… Prostate cancer (PCa) is one of the most common cancers in men. In the year 2020, an …
-resistant prostate cancer (mCRPC). The long-term prognosis for patients with mCRPC is poor, …

… the management of advanced prostate cancer provides a range of treatment options with
notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the …

… of mCRPC. In order to help comprehensively understand latest advances in the treatment …
mCRPC and the mechanisms of drug resistance, we summarize current therapies for mCRPC …

… DDR = defective DNA repair; FPKM = Fragments Per Kilobase of transcript per Million
mapped reads; mCRPC = metastatic castration-resistant prostate cancer; PSMA = …

… of metastatic castration-resistant prostate cancer (mCRPC), increasing options available to
… of men with mCRPC. Toward this effort, recent studies evaluated mCRPC treatment patterns …

… Prospective, noninterventional analysis of patient record data in the multicenter Prostate
Cancer Registry (PCR) of men with mCRPC. The data were collected in 16 countries with the …

… metastatic castration-resistant prostate cancer (mCRPC), of … types of cancer, but only a
marginal benefit for mCRPC, at … nature of the prostate tumor microenvironment, including …

… Eligible patients had to be diagnosed with prostate cancer (defined as histologic confirmation
of prostate cancer or as concluded by the treating doctor based on elevated PSA and …

… Metastatic castration-resistant prostate cancer (mCRPC) spreads quickly and does not
respond to surgical or medical castration. It is defined as serum testosterone level <50 ng/dL …

… Metastatic castration-resistant prostate cancer (mCRPC) is a latestage … , mCRPC still
remains a lethal disease. Identification of specific novel predictive biomarker mutations in mCRPC …